RAREのチャート
RAREの企業情報
| symbol | RARE |
|---|---|
| 会社名 | Ultragenyx Pharmaceutical Inc （ウルトラジェニックス・ファ―マシュ―ティカル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ウルトラジェニクス・ファーマシューティカル（Ultragenyx Pharmaceutical Inc.）は臨床段階のバイオ医薬品会社である。同社は、遺伝病の治療のための製品の特定、取得、開発、および商品化に注力している。臨床段階のパイプラインは、生物製剤（モノクローナル抗体と酵素補充療法を含む）と低分子基質置換療法の2つの製品カテゴリーで構成される。生物学的カテゴリーの製品候補には、KRN23（UX023）および組換えヒトβグルクロニダーゼ（rhGUS）（UX003）が含まれる。小分子カテゴリーの製品候補には、UX007およびアセネラミン酸徐放性（Ace-ER）（UX001）が含まれる。また、組換えヒトプロテインカテプシン-A（rhPPCA）も開発中である。KRN23は完全ヒトモノクローナル抗体である。rhGUSは、静脈内（IV）酵素補充療法である。UX007は基質補充療法です。GNEミオパチーの治療のためにエースERを開発中である。rhPPCAは前臨床開発中である。 ウルトラジェニックス・ファ―マシュ―ティカルは、米国のバイオ医薬品企業。消耗性代謝性遺伝子疾患の治療薬の開発、商品化に従事。X連鎖低リン血症の治療用ヒトモノクロ―ナル抗体、ムコ多糖症7向け酵素補充療法、およびリソソ―ム蓄積症向け前臨床開発における酵素補充療法などの生物製剤に加え、トリヘプタノインなどの基質補充療法の開発を手掛ける。 Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. |
| 本社所在地 | 60 Leveroni Court Novato CA 94949 USA |
| 代表者氏名 | Daniel G. Welch ダニエル・G・ウェルチ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 415-483-8800 |
| 設立年月日 | 40269 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 520人 |
| url | www.ultragenyx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/rare |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -356.08500 |
| 終値（lastsale） | 74.72 |
| 時価総額（marketcap） | 3749625715.04 |
| 時価総額 | 時価総額（百万ドル） 3314.043 |
| 売上高 | 売上高（百万ドル） 26.08300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2766.911 |
| 当期純利益 | 当期純利益（百万ドル） -112.93300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ultragenyx Pharmaceutical Inc revenues increased from $0K to $23.5M. Net loss decreased 84% to $22.5M. Revenues reflect Product sales increase from $0K to $3.6M. Lower net loss reflects Interest Income increase of 87% to $4.2M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.35 to -$0.43. |
RAREのテクニカル分析
RAREのニュース
Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference 2021/08/04 12:30:00 Intrado Digital Media
NOVATO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President will participate in a panel titled Miss Con-GENE-iality - Updates in Gene Tx on Wednesday, August 11, 2021 at the Wedbush PacGrow Healthcare Conference at 12:00 PM ET.
Ultragenyx Pharmaceutical (RARE) Investor Presentation - Slideshow 2021/08/03 14:50:57 Seeking Alpha
Ultragenyx Pharmaceutical Inc.''s (RARE) CEO Emil Kakkis on Q2 2021 Results - Earnings Call Transcript 2021/08/03 04:28:09 Seeking Alpha
Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update 2021/08/02 20:05:00 Intrado Digital Media
Second quarter 2021 total revenue of $87.0 million including Crysvita 1 revenue to Ultragenyx of $44.7 million
Ultragenyx''s mRNA encoding enzyme receives FDA Orphan Drug designation 2021/06/24 20:50:16 Seeking Alpha
Ultragenyx Pharmaceutical Inc. (RARE) gains 0.9950% for June 09 - Equities News 2021/06/14 00:30:26 Equities
Ultragenyx Pharmaceutical Inc. (RARE) gains 0.9950% for June 09 Equities.com
Regulatory actions for June 11, 2021 2021/06/11 15:00:00 BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Direct, Genetx, Moderna, Purdue, Soligenix, Ultragenyx.
Ultragenyx to Present at Jefferies Virtual Healthcare Conference 2021/05/26 12:31:00 GlobeNewswire
NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET.
Ultragenyx Pharmaceutical Inc. (RARE) gains 0.9950% for June 09 - Equities News 2021/06/14 00:30:26 Equities
Ultragenyx Pharmaceutical Inc. (RARE) gains 0.9950% for June 09 Equities.com
Regulatory actions for June 11, 2021 2021/06/11 15:00:00 BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Direct, Genetx, Moderna, Purdue, Soligenix, Ultragenyx.
Ultragenyx to Present at Jefferies Virtual Healthcare Conference 2021/05/26 12:31:00 GlobeNewswire
NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company''s Chief Executive Officer and President, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 PM ET.
Ultragenyx Pharmaceu (RARE) falls 2.52% for May 19 2021/05/19 22:00:21 Equities
Ultragenyx Pharmaceu (NASDAQ: RARE) shares fell -2.52% to end trading Wednesday at $108.62 per share - a net change of $-2.81. Shares traded between $112.78 and $107.71 throughout the day. 232646 shares of Ultragenyx Pharmaceu exchanged hands. Visit Ultragenyx Pharmaceus profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Ultragenyx Pharmaceu and to follow the companys latest updates, you can visit the companys profile page here: Ultragenyx Pharmaceus Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices.